Key Points
- CEO Jurgi Camblong sold about 91,569 shares across several transactions (including 17,473 shares on April 15 at an average $5.00, which generated ~$87K and reduced his stake by 0.48% for that trade).
- All trades were executed under pre-arranged Rule 10b5-1 plans and many were tax-withholding sales tied to vested awards, which mitigates governance concerns but increases the company’s float.
- SOPH remains unprofitable: it missed March-quarter EPS (-$0.28 vs. -$0.20 expected), shows negative net margins and ROE, and analysts expect roughly -0.96 EPS for the year despite mixed coverage and an average price target around $7.50.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) President Ross Muken sold 2,800 shares of SOPHiA GENETICS stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $4.96, for a total transaction of $13,888.00. Following the completion of the sale, the president owned 682,432 shares of the company's stock, valued at approximately $3,384,862.72. This trade represents a 0.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ross Muken also recently made the following trade(s):
- On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $21,143.92.
- On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.69, for a total transaction of $17,292.03.
- On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
- On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,484.24.
- On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,804.88.
- On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $5,666.57.
SOPHiA GENETICS Trading Up 1.0%
Shares of NASDAQ SOPH opened at $5.12 on Friday. The stock's 50 day moving average price is $4.75 and its two-hundred day moving average price is $4.72. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The stock has a market capitalization of $350.67 million, a P/E ratio of -10.04 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have weighed in on SOPH. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday. Guggenheim boosted their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of "Hold" and an average target price of $7.50.
Check Out Our Latest Stock Report on SOPH
Trending Headlines about SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS' AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at a major NCI-designated center, which could drive recurring software volume and credibility with large U.S. health systems. Mount Sinai collaboration
- Positive Sentiment: Sector tailwind — coverage highlighting Mount Sinai’s use of AI to speed genomic testing reinforces demand for AI-driven genomics platforms like SOPHiA DDM, supporting adoption and long-term revenue potential. Healthcare IT News
- Positive Sentiment: Analyst interest — several firms have set $7.00 targets and issued buy opinions (e.g., Guggenheim, BTIG), giving investors an upside reference versus current levels. Analyst coverage
- Neutral Sentiment: Insider selling activity — multiple insiders (CEO Jurgi Camblong, President Ross Muken and others) disclosed sales totaling tens of thousands of shares in mid-April. All trades were executed under pre-arranged Rule 10b5-1 plans and many were described as tax-withholding sales tied to vested awards, which reduces immediate governance concern but increases float. SEC Form 4 (example)
- Negative Sentiment: Underlying profitability risks — the company reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), with negative net margins and a substantial negative ROE. Analysts still expect FY losses (consensus around -0.96 EPS), highlighting ongoing path-to-profitability concerns that can cap multiple expansion. Earnings & metrics
Hedge Funds Weigh In On SOPHiA GENETICS
Several institutional investors have recently modified their holdings of SOPH. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth about $48,000. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS during the 3rd quarter valued at about $49,000. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS in the 4th quarter worth about $49,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS in the 4th quarter worth about $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. Institutional investors own 31.59% of the company's stock.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
